Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Thiamylal. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.50 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.50 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiamylal SCHEMBL1666144 | 0.98 | MMP9 (0.79) | MMP9LMNACYP3A4NR1I2ALDH1A1 | |
| Thiamylal SCHEMBL548050 | 0.98 | MMP9 (0.79) | MMP9LMNACYP3A4NR1I2ALDH1A1 | |
| Thiamylal SCHEMBL1003375 | 0.91 | MMP9 (0.69) | MMP9LMNACYP3A4NR1I2ALDH1A1 | |
| Secobarbital SCHEMBL41182 | 0.89 | MMP9 (0.97) | MMP9LMNACYP3A4NR1I2ALDH1A1 | |
| Secobarbital SCHEMBL614906 | 0.89 | MMP9 (0.97) | MMP9LMNACYP3A4NR1I2ALDH1A1 | |
| Secobarbital SCHEMBL7599361 | 0.89 | MMP9 (0.97) | MMP9LMNACYP3A4NR1I2ALDH1A1 | |
| Secobarbital SCHEMBL8085730 | 0.87 | MMP9 (1.00) | MMP9LMNACYP3A4NR1I2ALDH1A1 | |
| Secobarbital SCHEMBL80735 | 0.87 | MMP9 (1.00) | MMP9LMNACYP3A4NR1I2ALDH1A1 | |
| Secobarbital SCHEMBL80734 | 0.87 | MMP9 (1.00) | MMP9LMNACYP3A4NR1I2ALDH1A1 | |
| Secobarbital SCHEMBL41181 | 0.87 | MMP9 (1.00) | MMP9LMNACYP3A4NR1I2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 757 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200187851-A1 | PERIODONTAL DISEASE STRATIFICATION AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2020-06-18 | — | — | US | claimed |
| US-10583099-B2 | Isotope enhanced ambroxol for long lasting autophagy induction | UNM RAINFOREST INNOVATIONS | 2020-03-10 | — | — | US | claimed |
| US-20190145960-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2019-05-16 | — | — | US | claimed |
| EP-3470536-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | The J. David Gladstone Institutes (US) | 2019-04-17 | — | — | EP | claimed |
| US-10184933-B2 | Compositions, systems and methods for gene expression noise drug screening and uses thereof | The J. David Gladstone Industries (US) | 2019-01-22 | — | — | US | claimed |
| US-20160245796-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | THE J. DAVID GLADSTONE INSTITUTES (US) | 2016-08-25 | — | — | US | claimed |
| EP-3052662-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | The J. David Gladstone Institutes (US) | 2016-08-10 | — | — | EP | claimed |
| US-9179994-B2 | Implantable film/mesh composite | COVIDIEN LP (US) | 2015-11-10 | — | — | US | claimed |
| US-9005308-B2 | Implantable film/mesh composite for passage of tissue therebetween | COVIDIEN LP (US) | 2015-04-14 | — | — | US | claimed |
| WO-2015051035-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | THE J. DAVID GLADSTONE INSTITUTES (US) | 2015-04-09 | — | — | WO | claimed |
| US-20130102959-A1 | Implantable Film/Mesh Composite | COVIDIEN LP (US) | 2013-04-25 | — | — | US | claimed |
| US-20130103060-A1 | Implantable Film/Mesh Composite | COVIDIEN LP (US) | 2013-04-25 | — | — | US | claimed |
| US-20130030360-A1 | Implantable Devices Including A Mesh And A Pivotable Film | TYCO HEALTHCARE GROUP LP, (US) | 2013-01-31 | — | — | US | claimed |
| US-7534859-B2 | Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-19 | — | — | US | claimed |
| EP-1095136-B1 | CELLS AND ANIMALS DEFICIENT IN PROTEIN KINASE C EPSILON | UNIV CALIFORNIA (US) | 2009-03-18 | — | — | EP | claimed |
| US-20040191898-A1 | Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-09-30 | — | — | US | claimed |
| US-20020124272-A1 | PROTEIN KINASE C EPSILON AS MODULATOR OF ANXIETY, ALCOHOL CONSUMPTION AND SELF-ADMINISTRATION OF DRUGS OF ABUSE | ERNEST GALLO CLINIC AND RESEARCH CENTER | 2002-09-05 | — | — | US | claimed |
| EP-1095136-A1 | CELLS AND ANIMALS DEFICIENT IN PROTEIN KINASE C EPSILON | Messing, Robert O. (US) | 2001-05-02 | — | — | EP | claimed |
| WO-2000001805-A1 | CELLS AND ANIMALS DEFICIENT IN PROTEIN KINASE C EPSILON | MESSING ROBERT O (US) | 2000-01-13 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10583099-B2 | Isotope enhanced ambroxol for long lasting autophagy induction | BECN1, TFEB, ATG7 | GABRB3 604/4885GABRA2 846/4885GABRB2 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.